The long-term safety and efficacy of the cholesterol-lowering drug alirocumab have not yet been established. In a recent study, researchers assessed the effects of prolonged use of alirocumab compared with...
The ACC has updated its 2016 expert consensus decision pathway for the use of non-statin drugs for the lowering of LDL cholesterol in patients with atherosclerotic cardiovascular disease.
A recent study examined the efficacy of an experimental cholesteryl ester transfer protein inhibitor for lowering major adverse cardiovascular events in patients with high-risk vascular disease.
The American Association of Clinical Endocrinologists and the American College of Endocrinology have released new guidelines for the treatment and management of dyslipidemia and the prevention of...
In a recent expert-led presentation at the Practial Updates in Primary Care Virtual Series, Seth S. Martin, MD, MHS, and Daniel E. Soffer, MD, reviewed current evidence and clinical strategies for using...
A recent report from a non-profit, independant research group addresses the cost-effectiveness and budgetary impact of treatment with PCSK9 inhibitors.
